Guidant Considers Alternatives As Court Enjoins Paclitaxel DELIVER Data
This article was originally published in The Gray Sheet
Guidant is exploring a supply arrangement that would be consistent with Cook, Inc.'s original licensing agreement with Angiotech Pharmaceuticals in moving forward with a paclitaxel-eluting stent platform
You may also be interested in...
Boston Scientific's plans to change the design of its upcoming TAXUS V study in the U.S. suggest that the company is leaning toward the slow-release formulation of paclitaxel for its drug-eluting stent development program
Guidant's $3 bil. purchase of Cook Group does not represent a "change of ownership" under the terms of a 1997 licensing agreement between subsidiary Cook, Inc., Angiotech Pharmaceuticals and Boston Scientific, Guidant asserts
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.